Overview

A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone

Status:
Completed

Trial end date:
2015-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the safety and efficacy of multiple dose levels of the investigational product (study drug), IPI-145, in combination with methotrexate compared to methotrexate alone in subjects with active moderate-to-severe Rheumatoid Arthritis.

Phase:

Phase 2

Details

Lead Sponsor:

Infinity Pharmaceuticals, Inc.
SecuraBio

Treatments:

Methotrexate